Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy
Status:
Terminated
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase 2a clinical study designed to evaluate the safety and efficacy of
AVB-S6-500 in patients with IgA Nephropathy (IgAN). Approximately 24 patients will be
enrolled. Several dose levels of AVB-S6-500 may be evaluated.